SELLAS Life Sciences Group, Inc. (SLS) Cash Flow Statement

The OCF/NI ratio hovering near or above 1.0 in most quarters suggests that reported net losses closely track actual cash consumption, with working capital swings occasionally distorting the relationship. For instance, 2025Q1 saw OCF exceed net loss by 56%, driven by a $3.9M working capital outflow, while 2025Q4 showed OCF at only 64% of net loss due to a $2.1M working capital inflow. This volatility implies that cash burn is fundamentally tied to operating losses rather than accrual adjustments, reinforcing the severity of the cash drain.

While the absolute FCF deficit remains substantial, the trend shows a narrowing from the -$10.8M peak in early 2024 to a range of -$7M to -$9M in recent quarters, indicating some cost containment. However, with no revenue and FCF margins undefined, the company remains entirely dependent on external financing to sustain operations. The stabilization in burn rate may reflect management's cost-cutting efforts, but it does not alleviate the fundamental need for capital.

The absence of capex suggests that the company's clinical-stage business model requires little physical infrastructure, with spending concentrated in R&D and SG&A. This low capital intensity means that free cash flow is essentially equal to operating cash flow, and any future growth would likely require significant capital injections for manufacturing or commercialization. Investors should monitor whether this zero-capex trend persists as the company advances its pipeline.

The erratic working capital adjustments, such as the -$3.9M outflow in 2025Q1 and +$2.1M inflow in 2025Q4, suggest that SELLAS's cash flow is sensitive to the timing of vendor payments and clinical trial expenses. These swings can temporarily mask or exaggerate the underlying burn rate, making it essential to look at multi-quarter averages. The lack of revenue means working capital is primarily driven by prepaid expenses and accrued liabilities, which may indicate management's efforts to manage cash outflows.

The complete absence of capital deployment activities underscores that the company is in a survival mode, conserving every dollar for clinical development and general operations. This is typical for a pre-revenue biotech, but it also means that shareholder returns are entirely dependent on future value creation from the pipeline. The lack of buybacks or dividends is not a negative signal per se, but it highlights the company's reliance on external capital to fund its burn.